Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lance A. Liotta has a total of 422 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The proteome comes of age, but precision oncology needs functional maps

    by Emanuel Petricoin, Thomas Conrads, Lance Liotta

  • Open Access

    The Role of EZH2 in Malignant Pleural Mesothelioma and Beyond: Current Practice and Future Perspectives

    by Mehmet Kucukoner, Tarik Demir, Abduljalil Mohammed Alsubaie, Ulas Alabalik, Aisha K Ibrahim, Mariaelena Pierobon, Lance Liotta

    Purpose of Review: Malignant pleural mesothelioma (MPM) remains a rare but highly aggressive malignancy with limited treatment options and poor prognosis. For nearly twenty years, platinum–pemetrexed chemotherapy has persisted as the unchanged standard treatment; although recent progress in immunotherapy has modestly disrupted this therapeutic plateau, survival outcomes remain disappointingly limited. This review aims to provide a comprehensive overview of the epigenetic landscape of MPM, focusing particularly on the oncogenic and therapeutic implications of enhancer of zeste homolog 2 (EZH2), and to discuss its potential as a target for novel therapeutic strategies and combination regimens. Recent Findings: Epigenetic dysregulation has emerged as a central driver of mesothelioma pathogenesis. EZH2, the catalytic component of the polycomb repressive complex 2 (PRC2), mediates histone H3K27 trimethylation, silencing tumor suppressor genes and promoting malignant transformation. In addition to its canonical role, EZH2 has non-canonical oncogenic effects that modulate transcription, apoptosis, DNA repair, and immune evasion. High EZH2 expression correlates with BAP1 loss, which enhances chromatin remodeling defects and disease aggressiveness. Preclinical and early clinical data demonstrate that EZH2 inhibitors—including tazemetostat, valemetostat, GSK126, EPZ011989, tulmimetostat, and novel PROTAC-based degraders such as MS1943—can suppress tumor progression, modulate the tumor immune microenvironment, and restore therapeutic sensitivity. Furthermore, combination approaches integrating EZH2 inhibition with chemotherapy or immune checkpoint blockade show synergistic potential in overcoming resistance. Summary: EZH2 represents a pivotal epigenetic regulator and a promising therapeutic target in MPM. Further understanding the dual canonical and non-canonical roles of EZH2 in tumor biology will be key to optimizing targeted and combinatorial treatment strategies. Future research should focus on translating EZH2 inhibition into clinical benefit, identifying predictive biomarkers of response, and exploring rational combinations with chemotherapy, targeted drugs, or immunotherapy to improve survival outcomes in mesothelioma patients.


    • 8 June 2026
      • Vol. 28  (1)
    Open Access

    The Role of EZH2 ın Malıgnant Pleural Mesothelıoma and Beyond: Current Practıce and Future Perspectıves

    by Mehmet Kucukoner, Tarik Demir, Abduljalil Mohammed Alsubaie, Ulas Alabalik, Aisha K Ibrahim, Mariaelena Pierobon, Lance Liotta

    Malignant pleural mesothelioma (MPM) remains a rare but highly aggressive malignancy with limited treatment options and poor prognosis. For nearly twenty years, platinum–pemetrexed chemotherapy has persisted as the unchanged standard treatment; although recent progress in immunotherapy has modestly disrupted this therapeutic plateau, survival outcomes remain disappointingly limited. This review aims to provide a comprehensive overview of the epigenetic landscape of MPM, focusing particularly on the oncogenic and therapeutic implications of enhancer of zeste homolog 2 (EZH2), and to discuss its potential as a target for novel therapeutic strategies and combination regimens. Epigenetic dysregulation has emerged as a central driver of mesothelioma pathogenesis. EZH2, the catalytic component of the polycomb repressive complex 2 (PRC2), mediates histone H3K27 trimethylation, silencing tumor suppressor genes and promoting malignant transformation. In addition to its canonical role, EZH2 has non-canonical oncogenic effects that modulate transcription, apoptosis, DNA repair, and immune evasion. High EZH2 expression correlates with BAP1 loss, which enhances chromatin remodeling defects and disease aggressiveness. Preclinical and early clinical data demonstrate that EZH2 inhibitors—including tazemetostat, valemetostat, GSK126, EPZ011989, tulmimetostat, and novel PROTAC-based degraders such as MS1943—can suppress tumor progression, modulate the tumor immune microenvironment, and restore therapeutic sensitivity. Furthermore, combination approaches integrating EZH2 inhibition with chemotherapy or immune checkpoint blockade show synergistic potential in overcoming resistance. EZH2 represents a pivotal epigenetic regulator and a promising therapeutic target in MPM. Further understanding the dual canonical and non-canonical roles of EZH2 in tumor biology will be key to optimizing targeted and combinatorial treatment strategies. Future research should focus on translating EZH2 inhibition into clinical benefit, identifying predictive biomarkers of response, and exploring rational combinations with chemotherapy, targeted drugs, or immunotherapy to improve survival outcomes in mesothelioma patients.


  • Open Access

    Characterization of Borrelia-Derived Extracellular Vesicles: Implications for Pathogenesis and Diagnostics

    by Barbara Birkaya, Ahana Byne, Sumaiya Irfan, Joseph Gallagher, Dominic Granato, Hayat Kharmoud, Andrea Blake Brothers, Elsa Ronzier, Amanda Haymond Still, Weidong Zhou, et al.

    The cause of chronic neurological effects associated with Lyme disease (LD) remains unclear. We propose that bacterial extracellular vesicles (BEVs) released by Borrelia burgdorferi, the causative agent of LD, exacerbate spirochete-induced damage and serve as a persistent source of antigenic stimulation. We showed that, over a 10-day period, in vitro cultures of B. burgdorferi B31 produced 38,000 BEVs per spirochete with a distinctive double-membrane structure and median diameter of 143.3 nm. BEVs contained known immunogenic and immunomodulatory molecules such as peptidoglycan, p66, flagellar filament protein (FlaB), basic membrane proteins A/B/D, BdrV, GroEL, CRASP-1, ErpA8, glycerophosphodiester phosphodiesterase, p37, OMS28, p13, OspA/B/C, VlsE, and outer membrane glycolipids (e.g., cholesteryl 6-O acyl beta D galactopyranoside). Chromosome-encoded 16S ribosomal RNA and cp32 plasmid-encoded OspE and terminase genes were also detected in the BEVs. Of the 45 Borrelia proteins identified in the urine of a C3H/HeJ murine model of Lyme disease, 14 were associated with BEVs. In human urine samples, 31 of 289 spirochete proteins detected in patients with either acute Lyme disease or persistent borreliosis post-treatment symptoms, including p66 and FlaB, were also BEV-associated. BEV treatment of HMC3 human microglial cells reduced phagocytic activity and triggered aberrant activation of inflammatory and immunometabolic pathways, including upregulation of interferon-alpha (IFN-α), aconitate decarboxylase 1 (Acod1), and Toll-like receptor 2 (TLR2) gene expression. BEVs also induced NRF2 nuclear translocation. In conclusion, these findings support that BEVs can amplify spirochete-induced damage and act as antigenic debris, driving dampened phagocytic activity and dysregulated inflammation, with implications for diagnostics and therapeutics targeting vesicle-mediated pathology.


  • Laser capture microdissection

    by Lance A. Liotta, Thomas P. Conrads, Marissa A. Howard, Robyn P. Araujo, Emanuel F. Petricoin

    The tissue microenvironment was once viewed as an impossibly complex heterogeneous ecosystem. Today, tools and data analysis methods probe tissues at multiple resolution levels, from subpopulations to individual cells and individual molecules. Laser capture microdissection (LCM) was one of the first technologies enabling spatial molecular interrogation in tissues, enabling the extraction of precise regions of tissue for downstream acquisition and analysis of multiple classes of molecular analytes — including nucleic acids, proteins, metabolites and lipids. By physically isolating targeted cells or tissue compartments under microscopic visualization, LCM preserves spatial context for downstream multiomic profiling. The approach is agnostic to tissue type, molecular target and analytical tool, providing a powerful platform for spatially resolved analysis of tissue heterogeneity, microenvironment interactions and region-specific signatures. The attributes of LCM have drawn a large and diverse community of users who have imaginatively elevated the technology and its applications far beyond the early versions of LCM. In this Primer, we provide examples of how and when to use LCM and discuss its use with other spatial profiling platforms, providing an essential component of large-scale clinical research trials, revealing disease mechanisms and identifying predictors of therapeutic efficacy. Finally, we explore how the next generation of LCM and companion technologies will help to shape the personalized, designer therapies of the future.


  • Open Access

    Application of Ensemble Machine Learning to Metabolomic Data Identifies Metabolites Associated with Macrophage Polarization

    by Aadi Gannavaram, Rahul Paul, Spyros Karaiskos, Marissa Howard, Lance Liotta, Padmanabhan Seshaiyer

    Towards developing quantitative models of anti-tumor activities of macrophages, we evaluated the effects of cytokines, tumor exosomes, and polarization states of macrophages in a tumor microenvironemnt using a system of differential equations. We modeled the non-linear dynamics of macrophage polarization states (M0/M1/M2), tumor cell killing by macrophages, and evasion of macrophage mediated killing by tumor originated extracellular vesicle decoys. Solving these coupled differential equations using numerical approaches, showed that the rate of macrophage polarization into the M1 state is the critical determinant of anti-tumor activity mediated by M1 polarized macrophages. To determine what metabolomic factors correlate with the polarization of naïve macrophage into anti-tumor M1 or pro-tumor M2 phenotypes, we performed LC/MS-based untargeted metabolomic analysis. Statistical analysis using Python-Scikit-learn was performed on the metabolomic data from naïve, M1 or M2 polarized murine macrophages followed by multiple feature selection methods. Application of ensemble machine learning methods to both secreted and cell associated metabolites revealed novel molecules of fatty acid metabolism to be the main mediators of polarization. Integration of ensemble machine learning feature-ranking tools into our analysis of metabolomic data identified new potential targets in macrophage metabolism for enhancing anti-tumor activities.

  • Open Access

    hTERT-Immortalized Mesenchymal Stem Cell-Derived Extracellular Vesicles: Large-Scale Manufacturing, Cargo Profiling, and Functional Effects in Retinal Epithelial Cells

    by Jessica Hindle, Anastasia Williams, Yuriy Kim, Dongsung Kim, Kajal Patil, Pooja Khatkar, Quinn Osgood, Collin Nelson, David A. Routenberg, Marissa Howard, et al.

    As the economic burden associated with vision loss and ocular damage continues to rise, there is a need to explore novel treatment strategies. Extracellular vesicles (EVs) are enriched with various biological cargo, and there is abundant literature supporting the reparative and immunomodulatory properties of stem cell EVs across a broad range of pathologies. However, one area that requires further attention is the reparative effects of stem cell EVs in the context of ocular damage. Additionally, most of the literature focuses on EVs isolated from primary stem cells; the use of EVs isolated from human telomerase reverse transcriptase (hTERT)-immortalized stem cells has not been thoroughly examined. Using our large-scale EV-manufacturing platform, we reproducibly manufactured EVs from hTERT-immortalized mesenchymal stem cells (MSCs) and employed various methods to characterize and profile their associated cargo. We also utilized well-established cell-based assays to compare the effects of these EVs on both healthy and damaged retinal pigment epithelial cells. To the best of our knowledge, this is the first study to establish proof of concept for reproducible, large-scale manufacturing of hTERT-immortalized MSC EVs and to investigate their potential reparative properties against damaged retinal cells. The results from our studies confirm that hTERT-immortalized MSC EVs exert reparative effects in vitro that are similar to those observed in primary MSC EVs. Therefore, hTERT-immortalized MSCs may represent a more consistent and reproducible platform than primary MSCs for generating EVs with therapeutic potential.


  • Open Access

    Autophagy Deregulation in HIV-1-Infected Cells Increases Extracellular Vesicle Release and Contributes to TLR3 Activation

    by Catherine DeMarino, Maria Cowen, Anastasia Williams, Pooja Khatkar, Fardokht A. Abulwerdi, Lisa Henderson, Julia Denniss, Michelle L. Pleet, Delores R. Luttrell, Iosif Vaisman, et al.

    Human immunodeficiency virus type 1 (HIV-1) infection can result in HIV-associated neurocognitive disorder (HAND), a spectrum of disorders characterized by neurological impairment and chronic inflammation. Combined antiretroviral therapy (cART) has elicited a marked reduction in the number of individuals diagnosed with HAND. However, there is continual, low-level viral transcription due to the lack of a transcription inhibitor in cART regimens, which results in the accumulation of viral products within infected cells. To alleviate stress, infected cells can release accumulated products, such as TAR RNA, in extracellular vesicles (EVs), which can contribute to pathogenesis in neighboring cells. Here, we demonstrate that cART can contribute to autophagy deregulation in infected cells and increased EV release. The impact of EVs released from HIV-1 infected myeloid cells was found to contribute to CNS pathogenesis, potentially through EV-mediated TLR3 (Toll-like receptor 3) activation, suggesting the need for therapeutics to target this mechanism. Three HIV-1 TAR-binding compounds, 103FA, 111FA, and Ral HCl, were identified that recognize TAR RNA and reduce TLR activation. These data indicate that packaging of viral products into EVs, potentially exacerbated by antiretroviral therapeutics, may induce chronic inflammation of the CNS observed in cART-treated patients, and novel therapeutic strategies may be exploited to mitigate morbidity.


  • Open Access

    Universal structures for adaptation in biochemical reaction networks

    by Robyn P. Araujo, Lance A. Liotta

    At the molecular level, the evolution of life is driven by the generation and diversification of adaptation mechanisms. A universal description of adaptation-capable chemical reaction network (CRN) structures has remained elusive until now, since currently-known criteria for adaptation apply only to a tiny subset of possible CRNs. Here we identify the definitive structural requirements that characterize all adaptation-capable collections of interacting molecules, however large or complex. We show that these network structures implement a form of integral control in which multiple independent integrals can collaborate to confer the capacity for adaptation on specific molecules. Using an algebraic algorithm informed by these findings, we demonstrate the existence of embedded integrals in a variety of biologically important CRNs that have eluded previous methods, and for which adaptation has been observed experimentally. This definitive picture of biological adaptation at the level of intermolecular interactions represents a blueprint for adaptation-capable signaling networks across all domains of life, and for the design of synthetic biosystems.


  • Open Access

    Supplementary Table 1 from Systems Analysis of the NCI-60 Cancer Cell Lines by Alignment of Protein Pathway Activation Modules with “-OMIC” Data Fields and Therapeutic Response Signatures

    by Giulia Federici, Xi Gao, Janusz Slawek, Tomasz Arodz, Amanuel Shitaye, Julia D. Wulfkuhle, Ruggero De Maria, Lance A. Liotta, Emanuel F. Petricoin

    PDF file - 107K, List of antibodies against total-, phospho- and cleaved-proteins, with dilutions used for RPPA analysis.